Cell MedX Corp (CMXC) reported a negative net income of $66,919 in QQ1 2025, with operating income of −$73,845 and EBITDA of −$58,066. Revenue data for QQ1 2025 was not disclosed in the provided dataset, limiting top-line assessment. Relative to the prior year, operating income shows a YoY improvement of 4.04% and a QoQ improvement of 36.86%, while net income improves 13.04% YoY and 46.45% QoQ, yet remains meaningfully negative. The company continues to burn cash, posting negative cash flow from operations of $22,917 and a sequential decrease in cash to $20,552 at quarter end, from $43,415 at the beginning of the period.
From a balance sheet perspective, CMXC carries a highly precarious liquidity position: total current liabilities exceed assets by a wide margin (total current liabilities of $931,127 vs. total assets of $22,397) and stockholders’ equity is negative at −$908,730. Short-term debt stands at $321,288 and net debt is $300,736. The liquidity metrics are severely stressed, with current, quick, and cash ratios all around 0.02–0.03, indicating an extremely tight runway absent additional capital or a meaningful revenue/sales recovery. Management commentary on QQ1 2025 in the available materials is not provided, limiting the ability to confirm execution plans or near-term guidance.
Overall, the investment thesis for CMXC in QQ1 2025 rests on the potential commercialization and adoption of its eBalance Pro System (professional use) and eBalance Home System (home wellness/pain management). However, the current cash burn, negative equity, and lack of disclosed revenue create substantial risk. Investors should monitor any forthcoming guidance on revenue ramp, cost controls, and financing plans, as well as any strategic moves (partnerships, licensing, or equity financings) that could restore liquidity and improve profitability trajectory.